pharmaphorum November 9, 2023
The FDA has approved Takeda’s Fruzaqla for a group of patients with relapsed or refractory metastatic colorectal cancer, offering another option for patients who have exhausted earlier lines of therapy.
Takeda said that Fruzaqla (fruquintinib) has been cleared for use in adults with CRC who have been previously treated with chemotherapy, an anti-VEGF drug, and – if appropriate – an anti-EGFR therapy.
The Japanese drugmaker said the oral drug – which inhibits all three VEGF receptor kinases – is the first targeted, chemotherapy-free therapy for metastatic CRC that can be used regardless of biomarker status or prior therapies to be approved by the FDA in more than a decade.
Takeda licensed ex-China rights to fruquintinib from Hutchmed earlier this year...
Today's Sponsors
Today's Sponsor